PI-RADS 4 or PI-RADS 5 Lesion on Prostate MRI: What Does It Mean?

If your prostate MRI report mentions a PI-RADS 4 or PI-RADS 5 lesion, it means that the radiologist has identified an area suspicious for clinically significant prostate cancer.

However, PI-RADS 4 or 5 does not itself diagnose prostate cancer. MRI estimates the likelihood that a suspicious area represents significant cancer; in most patients, confirmation requires a prostate biopsy.

The practical question is therefore:

“How suspicious is this lesion, and what should I do next?”

What is PI-RADS?

PI-RADS (Prostate Imaging Reporting and Data System) is a standardized system used for interpreting and reporting prostate MRI.

It grades suspicious areas within the prostate from PI-RADS 1 to PI-RADS 5, according to how likely they are to represent clinically significant prostate cancer.

PI-RADS Score	What it generally means
PI-RADS 1	Clinically significant cancer is highly unlikely
PI-RADS 2	Clinically significant cancer is unlikely
PI-RADS 3	Risk is indeterminate/equivocal
PI-RADS 4	Clinically significant cancer is likely
PI-RADS 5	Clinically significant cancer is highly likely

Therefore, PI-RADS 4 and PI-RADS 5 are considered suspicious MRI findings and generally require further evaluation.

What does “clinically significant prostate cancer” mean?

This is an important distinction.

Not every prostate cancer behaves aggressively or requires immediate treatment. Modern prostate-cancer diagnosis focuses particularly on finding cancers that are more likely to grow, progress or cause harm during a man's lifetime.

In contemporary practice, Grade Group 2 or higher prostate cancer is commonly considered clinically significant in the diagnostic setting.

The purpose of prostate MRI is therefore not simply to find every microscopic prostate cancer. It is primarily to identify areas where clinically meaningful disease may be present and guide biopsy toward those areas.

What does a PI-RADS 4 lesion mean?

A PI-RADS 4 lesion means that clinically significant prostate cancer is considered likely to be present.

It is a relatively high-suspicion finding, but it is not equivalent to a cancer diagnosis.

Some PI-RADS 4 lesions will prove benign on biopsy. Others may show low-grade cancer, while a substantial proportion will contain clinically significant prostate cancer.

This is why the MRI finding should be considered together with:

• PSA level

• PSA density

• Age

• Prostate volume

• Family history

• Previous biopsy results

• Location and size of the lesion

• Overall clinical risk

In most biopsy-naïve patients, a PI-RADS 4 lesion warrants serious consideration for MRI-targeted prostate biopsy.

What does a PI-RADS 5 lesion mean?

A PI-RADS 5 lesion represents the highest level of suspicion on prostate MRI.

It means that clinically significant prostate cancer is considered highly likely.

PI-RADS 5 lesions therefore deserve prompt specialist evaluation and, unless there is a specific reason not to proceed, usually require histological confirmation with prostate biopsy.

Importantly:

PI-RADS 5 still does not mean “100% cancer.”

Inflammation and some benign prostate abnormalities can occasionally mimic cancer on MRI. Histopathology remains necessary to determine whether cancer is present and, if so, its Grade Group.

Is PI-RADS 5 worse than PI-RADS 4?

Yes, in terms of the probability of clinically significant prostate cancer.

PI-RADS 5 represents a higher level of MRI suspicion than PI-RADS 4.

However, PI-RADS is not a cancer stage and not a Gleason score.

A PI-RADS 5 result does not automatically mean that the patient has advanced or aggressive prostate cancer. Likewise, a PI-RADS 4 lesion can sometimes contain high-grade disease.

Only biopsy can determine the histological grade of the tumour.

Does PI-RADS tell me the stage of prostate cancer?

No.

This is a common misunderstanding.

PI-RADS primarily communicates the likelihood of clinically significant prostate cancer being present within an MRI-visible lesion.

It is different from:

• Grade Group/Gleason score – tells us how the cancer looks microscopically

• TNM stage – describes how far the cancer has spread

• PSA – provides an important biochemical risk marker

MRI may separately describe findings suspicious for extraprostatic extension, seminal-vesicle invasion, lymph-node involvement or bone abnormalities, but these findings should not be confused with the PI-RADS score itself.

Why has my lesion been given a PI-RADS score?

Prostate MRI assesses several characteristics of prostate tissue.

The radiologist evaluates sequences including:

T2-weighted imaging

This provides detailed anatomical information about the prostate and is particularly important for assessing lesions within the transition zone.

Diffusion-weighted imaging (DWI)

Cancerous tissue often restricts the movement of water molecules. This can produce characteristic abnormalities on diffusion-weighted images and the ADC map.

Dynamic contrast enhancement

When contrast is used, areas showing characteristic early enhancement can provide additional information in selected situations.

The importance of each MRI sequence differs depending on whether the lesion lies within the peripheral zone or transition zone.

Does lesion size matter?

Yes, but size should not be interpreted independently of the other MRI features.

Under PI-RADS v2.1, lesion dimensions and certain findings such as evidence of extraprostatic extension can influence classification.

Your MRI report should therefore ideally describe:

• PI-RADS category

• Lesion size

• Exact location

• Peripheral or transition-zone origin

• Relationship to the prostate capsule

• Suspicion of extraprostatic extension

• Seminal-vesicle findings

• Prostate volume

These details can become important both for biopsy planning and, if cancer is subsequently confirmed, treatment planning.

What is the role of PSA density?

PSA density (PSAD) is one of the most useful additional pieces of information when interpreting prostate MRI.

It is calculated as:

PSA Density = PSA ÷ Prostate Volume

For example:

PSA = 6 ng/mL
Prostate volume = 60 mL
PSA density = 0.10 ng/mL/cc

Whereas:

PSA = 6 ng/mL
Prostate volume = 30 mL
PSA density = 0.20 ng/mL/cc

Both men have exactly the same PSA, but the second result may be more concerning because the PSA is disproportionately high relative to the size of the prostate.

PSA density is particularly useful when MRI findings are equivocal, but it also contributes to the overall risk assessment in men with suspicious lesions.

I have PI-RADS 4 or 5. Do I need a biopsy?

In most patients, a PI-RADS 4 or PI-RADS 5 lesion should be evaluated with prostate biopsy if the result will influence management.

The purpose of biopsy is to answer questions that MRI cannot:

1. Is this actually prostate cancer?

2. If cancer is present, what Grade Group is it?

These answers are essential before deciding whether a patient requires active surveillance, surgery, radiotherapy or another treatment strategy.

What type of prostate biopsy should be performed?

When MRI has already identified a PI-RADS 4 or 5 lesion, the suspicious area should generally be specifically targeted during biopsy.

This is known as an MRI-targeted prostate biopsy.

The biopsy may be performed using:

• MRI-ultrasound fusion targeting

• Cognitive MRI targeting

• In-bore MRI targeting in selected settings

Depending on the clinical situation, targeted cores may be combined with additional systematic or perilesional sampling.

Transperineal or transrectal biopsy?

Where expertise and facilities are available, the transperineal approach has become increasingly favoured.

In a transperineal biopsy, needles enter the prostate through the skin between the scrotum and anus rather than passing through the rectal wall.

Important advantages include a substantially lower risk of infectious complications and good access to different regions of the prostate.

The appropriate biopsy technique should nevertheless be individualized according to the lesion, patient characteristics and local expertise.

Can a PI-RADS 4 or 5 lesion still have a negative biopsy?

Yes.

A suspicious MRI does not guarantee that biopsy will demonstrate cancer.

A negative biopsy can occur because:

• The MRI abnormality was benign

• Inflammation mimicked cancer

• The lesion was difficult to target

• The biopsy did not adequately sample the lesion

• MRI interpretation overestimated the abnormality

But a negative biopsy does not always end the evaluation.

If a PI-RADS 4 or particularly PI-RADS 5 lesion remains highly suspicious despite a negative biopsy, the MRI, PSA density, biopsy technique and pathology should be reviewed carefully.

Selected patients may require repeat MRI, expert radiological review or repeat targeted biopsy.

My PSA is only mildly elevated. Should I still worry about PI-RADS 4 or 5?

A relatively low PSA does not automatically negate a suspicious MRI finding.

PSA should always be interpreted alongside:

Prostate volume + PSA density + MRI findings + age + family history + previous investigations

For example, a PSA of 5 ng/mL in a 100 mL prostate is different from a PSA of 5 ng/mL in a 25 mL prostate.

This is why treatment decisions should not be based on PSA or PI-RADS in isolation.

What if the biopsy confirms prostate cancer?

The next step depends primarily on:

• Grade Group/Gleason score

• PSA

• Clinical stage

• MRI findings

• Number and extent of positive biopsy cores

• Patient's age and general health

• Additional staging investigations when indicated

Importantly, a cancer diagnosis does not automatically mean surgery is necessary.

Selected low-risk cancers may be managed with active surveillance.

Clinically significant localized prostate cancers may be treated with radical prostatectomy or radiotherapy, while higher-risk or more advanced cancers may require multimodal treatment.

The biopsy therefore provides the missing information needed to move from “suspicion of cancer” to an individualized treatment decision.

How I approach a PI-RADS 4 or 5 MRI in clinical practice

The MRI score is important, but I would not interpret it in isolation.

The practical assessment is:

MRI lesion + PSA + PSA density + prostate volume + family history + previous biopsy + patient's age and overall health

For a biopsy-naïve patient with a technically adequate MRI showing a convincing PI-RADS 4 or PI-RADS 5 lesion, the usual next step is an appropriately targeted prostate biopsy.

If the MRI and clinical picture do not agree—for example, a highly suspicious lesion with an unexpectedly negative biopsy—the appropriate response is not simply to ignore either result. The MRI images, biopsy targeting and histopathology should be reconsidered together.

This multidisciplinary correlation is particularly important for persistent PI-RADS 5 lesions.

Frequently Asked Questions

Does PI-RADS 4 mean I definitely have prostate cancer?

No. PI-RADS 4 means clinically significant prostate cancer is likely, not certain. Histopathological confirmation is generally required.

Does PI-RADS 5 definitely mean cancer?

No. PI-RADS 5 represents very high suspicion, but benign conditions can occasionally mimic prostate cancer. Biopsy is required for diagnosis in most clinical situations.

Is PI-RADS 5 Stage 5 prostate cancer?

No. There is no “Stage 5” prostate cancer in this context. PI-RADS 5 is an MRI suspicion category, not a cancer stage.

Can prostatitis look like PI-RADS 4 or 5?

Yes. Inflammation can sometimes produce MRI abnormalities that mimic prostate cancer, which is one reason MRI alone cannot establish the diagnosis.

Can a PI-RADS lesion disappear?

Some abnormalities, particularly inflammatory changes, may change or resolve on subsequent MRI. However, a previously identified PI-RADS 4 or 5 lesion should not simply be ignored without appropriate clinical assessment.

Should a PI-RADS 4 lesion always be biopsied?

Most biopsy-naïve men with PI-RADS 4 lesions will be considered for targeted biopsy, but the decision should incorporate PSA density, previous investigations, comorbidities and whether diagnosing the cancer would alter management.

Should a PI-RADS 5 lesion be removed surgically?

Not based on MRI alone. A PI-RADS 5 lesion generally requires biopsy first. Treatment is determined only after considering the biopsy Grade Group, PSA, stage and individual patient factors.

The key message

PI-RADS 4 and PI-RADS 5 indicate increasing levels of suspicion for clinically significant prostate cancer—they do not themselves diagnose cancer.

A sensible pathway is:

PI-RADS 4/5 on MRI → assess PSA and PSA density → review clinical risk → MRI-targeted prostate biopsy → histopathology → risk classification → individualized management

The most important step is therefore not to panic about the PI-RADS number and not to ignore it either.

The MRI finding should be evaluated systematically so that clinically significant cancer is identified promptly while unnecessary treatment is avoided.

---

Evidence & References

1. American College of Radiology, European Society of Urogenital Radiology & AdMeTech Foundation. PI-RADS: Prostate Imaging Reporting and Data System, Version 2.1. PI-RADS 4 represents a high likelihood and PI-RADS 5 a very high likelihood that clinically significant prostate cancer is present.

2. European Association of Urology. EAU Guidelines on Prostate Cancer – Diagnostic Evaluation, 2026. Contemporary diagnostic pathways incorporate prostate MRI alongside PSA, PSA density and individualized risk assessment when determining the indication and approach to prostate biopsy.

3. American Urological Association/Society of Urologic Oncology. Early Detection of Prostate Cancer Guideline. MRI findings should be incorporated with other clinical risk factors when deciding on prostate biopsy, with the diagnostic objective focused on detecting clinically significant prostate cancer.

---

About the Author

Dr. Anshuman Singh
Uro-Oncology & Robotic Surgery

Dr. Anshuman Singh is a fellowship-trained uro-oncologist with a dedicated clinical focus on cancers of the prostate, urinary bladder, kidney, testis and penis, including minimally invasive and robotic uro-oncological surgery.

This article is intended for patient education and does not replace individualized medical consultation.